| Name | Title | Contact Details |
|---|
HealthSherpas mission is to help every American feel the comfort and security of having health coverage. HealthSherpa is the largest and fastest-growing individual health coverage exchange in the United States, simplifying access to ACA and Medicare health plans from both federal and state marketplaces. Our secure, integrated technology platform empowers insurance agents, agencies, and carriers to quickly and accurately serve and support individuals as they select and use quality, affordable health plans.
Grant Thornton una de las firmas líderes a nivel mundial de servicios profesionales de Auditoría, Consultoría de Negocio, Tecnología e Innovación y Asesoramiento Fiscal, Legal, Financiero, Laboral y Outsourcing. Pertenecemos a una de las organizaciones y red líderes en servicios profesionales en todo el mundo, Grant Thornton International, con más de 73.000 profesionales presentes en más de 147 mercados. En España contamos con un equipo multidisciplinar, transversal, con experiencia y visión empresarial, que da servicio a más de 4.000 clientes en 10 oficinas repartidas por el territorio nacional: Madrid, Barcelona, Bilbao, Castellón, Las Palmas, Murcia, Valencia, Pamplona y Zaragoza.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MotoRad Ltd. is a global manufacturer of automotive components, specializing in thermal management systems. Established in 1958 and originally known as Fishman Engineering Ltd., the company is now owned by Fortissimo Investment Funds and employs 156 people. In 2025, MotoRad reported an annual revenue of $28.7 million, with Matt Buchholz serving as CEO. The company develops and manufactures a range of thermal management solutions, including thermostats, caps, and sensors. These products are designed for internal combustion engines, hybrid vehicles, plug-in hybrids, and battery electric vehicles. MotoRad serves automotive OEMs, aftermarket distributors, and industrial applications, ensuring a high level of product availability and a 97.81% global fill rate to meet customer needs. The company emphasizes innovation and collaborative work environments, focusing on employee development and technological advancement.